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A systematic review about costing
methodology in robotic surgery: evidence
for low quality in most of the studies
Malene Korsholm1,2,5,6,7* , Jan Sørensen2,3, Ole Mogensen4,5, Chunsen Wu1,5, Kamilla Karlsen1,5 and Pernille T. Jensen1,5
Abstract
Objectives: The main objective of this review was to evaluate the methodological design in studies reporting
resource use and costs related to robotic surgery in gynecology.
Methods: Systematic searches were performed in the databases PubMed, Embase, Scopus, and The Centre for
Reviews and Dissemination database for relevant studies before May 2016. The quality of the methodological
design was assessed with items regarding methodology from the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS). The systematic review was reported according to the PRISMA guidelines.
Results: Thirty-two relevant studies were included. None of the reviewed studied fully complied with the CHEERS
methodological checklist. Background and objectives, Target population and subgroups and Setting and location were
covered in sufficient details in all studies whereas the Study perspective, Justification of the time horizon, Discount
rate, and Estimating resources and costs were covered in less than 50%. Most of the studies (29/32) used the health
care sector perspective whereas the societal perspective was applied in three studies. The time horizon was stated
in 18/32 of the studies.
Conclusions: The methodological quality of studies evaluating costs of robotic surgery was low. The longest
follow-up was 4 months and in general, the use of detailed cost data were lacking in most of the investigations.
Key determinants, such as purchasing, maintenance costs of the robotic platform, and the use of surgical equipment,
were rarely reported. If health care cost analyses lack transparency regarding cost drivers included it may not provide a
true foundation for decision-making.
Keywords: Economics, Robot-assisted laparoscopy, Cost analysis, Gynecologic surgery
Background
Previous systematic reviews comparing the cost-effect-
iveness of Robotic Minimally Invasive Surgery (RMIS)
with other surgical modalities found higher costs associ-
ated with RMIS. However, the conclusions were based
on limited evidence due to heterogeneity in study de-
signs, methodology, and time follow-up after surgery [1–
4]. In a recent review, key determinants causing higher
costs of RMIS compared to open- and laparoscopic
surgery were purchase and maintenance cost of the robot,
surgical equipment, and additional costs related to longer
operation time. The costs were, to a lesser extent, affected
by the lifespan of the robotic platform and the annual
number of robotic procedures [2].
The guiding principle for cost analysis is to identify the
“opportunity costs”, defined as the value of the next best
option [5]. Cost analyses are context specific and often
limited by the availability of data. Lack of adherence to
guiding principles and standards decreases transparency
and quality of cost analyses [6] which may lead to wrong
conclusions and decisions based on an insufficient
foundation.
The aim of the present systematic review was to evaluate
the methodological design employed in studies of resource
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use and costs related to RMIS within gynecology. We
furthermore assed if the reporting quality complied with
the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) statement [7]. Hence, the focus was
not to evaluate the cost of RMIS compared with other
surgical modalities, but primarily to evaluate different
methodological choices that may influence the validity of
cost analyses.
Methods
The systematic review was reported according to the
Preferred Reporting Items for Systematic Review and
Meta-Analyses (PRISMA) guidelines [8].
Eligibility criteria
We included randomized controlled trials, prospective
and retrospective cohorts, and case-control studies com-
paring the cost of hysterectomy conducted with RMIS
versus laparoscopic, open, and vaginal access.
Search
A systematic search was performed in the databases
PubMed, EMBASE, Scopus, and The Centre for Reviews
and Dissemination (CRD) database for relevant studies
before May 2016 with assistance of a librarian. No
language or date limits were imposed in the search. MK
developed the PubMed search strategy with input from
JS and PTJ. After the PubMed strategy was made, it was
adapted to the syntax and subject headings of the other
databases. Reference lists of included studies were exa-
mined for additional references [9].
Study selection
Two authors (MK and KK) independently screened the
titles and abstracts and obtained full text of all studies
for the reviewing in Covidence [10]. Covidence is a com-
ponent of Cochrane’s review production, a web-based
systematic review tool designed to facilitate the process
of screening and enables two reviewers to work effi-
ciently through the steps of a systematic review [10].
The same two authors examined the full text articles
and selected studies according to the inclusion criteria.
Any inconsistency in the identification of potentially
relevant papers was discussed until consensus.
Data collection process
The CHEERS recommendations attempt to optimize
reporting of health economic evaluations and consist of
24 items. We selected eight items from the CHEERS rec-
ommendations which were specifically related to the
methodological design and assessed important for the
reporting of costs [7]. The methodological Items included:
1) Background and objectives, 2) Target population and
subgroups, 3) Setting and location, 4) Study perspective,
5) Comparators, 6) Time horizon, 7) Discount rate, 8)
Estimating resources and costs. Further, we included items
related to cost aspects associated to the robotic platform.
The chosen items were translated into 12 questions,
against which each study was assessed and marked either
“yes”, “partly”, and “not available” and specification of the
time follow-up after surgery (Table 1). MK and KK evalu-
ated the quality of the methodological design in all studies
independently [7]. The same authors examined their find-
ings and any disagreement was discussed until consensus.
Table 1 Questions from CHEERS checklist
Section/items Items No Questions
Introduction
Background and objectives 3 Was an explicit statement of the broader context provided for the study?
Were the study questions and its relevance for health policy or practice decisions presented?
Methods
Target population and subgroups 4 Were the analyzed characteristics of the base case population and subgroups described, including
why they were chosen?
Setting and location 5 Were relevant aspects of the system(s) stated in which the decision(s) needed to be made?
Study perspective 6 Was the perspective of the study described and related to the costs being evaluated?
Comparators 7 Were the compared interventions or strategies describe and was it stated why they were chosen?
Time horizon 8 What was the time horizon?
Was the time horizon justified?
Discount rate 9 If relevant, which discount rate was applied?a
Estimating resources and costs 13 Was micro-costing applied?
Was the costs of purchasing the RMIS platform included?
Were the maintainance costs of RMIS reported (incl. depreciation and number of procedures)?
aNA: If time horizon is not more than a year
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Results
Study selection
We identified 763 references of which 32 met the inclu-
sion criteria. The search, screening and exclusions are
given in Fig. 1.
Study characteristics
The cost studies (Table 2) were published from 2008 to
2016 and originated from the U.S. (n = 21), Europe (n = 9),
and Canada (n = 2). In three studies, the cost analyses were
conducted within the framework of a cost-minimization
analysis [11, 12], one study used a cost-benefit framework
[13] and one study used activity based costing [14]. The
remaining studies reported on costing analyses.
Results of individual studies
A visual presentation of the CHEERS criteria and the
ranking of the quality assessment are shown in Table 3.
All 12 questions from the CHEERS recommendations
were marked either “yes”, “partly”, and “not available”
for each study. A “yes” was given 1 point, “partly” a ½
point and “not available” none points.
None of the studies reported all 12 questions; one
study (3%) was given 9.5 point [15], six studies (18.8%)
8–8.5 points [14, 16–20], three studies (9.4%) 7.5 point
[12, 21, 22], three studies (9.4%) 6–6.5 points [23–25],
fourteen studies (43.8%) 5–5.5 points [9, 26–37] and five
studies (12.5%) 4.5 point [13, 38–41].
Results from the 12 questions
“Background and objectives”, “Target population and
subgroups” and “Setting and location” were described in
all studies. Comparators were partly described in most
studies (30/32) but were fully reported in two studies
only. The study perspective was clearly stated in seven
studies but was not mentioned in 23 studies and only
Fig. 1 PRISMA flow chart for selection of included studies
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partly mentioned in two studies. Most of the studies
(n = 29) used the health care sector perspective whereas
the societal perspective was applied in three studies only
[24, 35, 37]. The societal perspective included return
to work/normal daily activity and estimated lost
wages [24, 35, 37]. The time horizon was stated in
18/32 studies but none provided a reason for their
choice of time horizon. Most studies reported from
the inpatient stay (n = 6) and the time horizon ranged
from inpatient stay to 4 months after discharge. One
Table 3 Results from CHEERS checklist.
Reported, Partly reported, Not reported
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study measured the cancer recurrence rate 2 years
after surgery but did not report the cost of the recur-
rence [19].
Seven studies estimated Resources and costs by
micro-costing (collection of detailed data on resources
used to assess costs of an activity) reporting detailed
data from a single hospital. The majority of cost items
derived from surgery and included the purchase and
maintenance costs of the robotic platform with depreci-
ation and yearly number of procedures [14–19, 22]. One
of the seven studies combined micro-costing with
gross-costing using hospital charge data but did not in-
clude detailed data on resource use [14]. The discount
rate was not reported in any of the studies due to the
short time horizon applied. The depreciation period of
the robotic lifespan ranged from five to 10 years in 8/32
of the studies and [12, 14–16, 18, 19, 22, 37] 7 years was
most frequently used (n = 5). The number of annual robotic
procedures ranged from 234 to 400 and was reported in
five studies [12, 14, 16–18]. The service agreement costs of
10% of the purchasing prize of the robot were reported in
five studies only [12, 15, 19, 22, 37].
From the index hospitalization Equipment costs
were the most common included cost items reported
from the operation (n = 18) and the exact numbers of
operation equipment costs were reported in six stu-
dies [9, 12, 14, 16, 17, 42]. Other costs included: costs
of the operating room (n = 18), room and board
(costs of regular room and any intensive care unit
stay) (n = 14), other cost categories (e.g. pathology,
laboratory, central supply, pharmacy, and infusion)
(n = 14), operation time and costs of anesthesia (n = 13).
Less frequently included costs were cleaning and sterili-
zing equipment (n = 4). Other reported costs not related
to the index hospitalization were costs of the patient being
morbidly obese and insurance coverage (n = 3). An over-
view of reported costs is presented in Fig. 2.
Discussion
Our study showed that only few cost studies complied
with the methodological items recommended by the
CHEERS checklist. We identified critical design issues..
Ideally, a broader cost perspective is recommended to
clarify resource use from hospitalization and outside the
healthcare system. The time horizon should include re-
source consumption and costs following the intervention
e.g. include rehabilitation.
Only few studies [11, 37, 43] included the societal
perspective thus avoiding potentially important cost
elements such as estimated costs related to the use
of patient time e.g. return to labor market, transpor-
tation, and costs from the non-health care sector.
Collecting costs from the hospital perspective, only
short-term cost implications are considered. When
the loss of productivity or other patient related use
outside the hospital is not included; additional costs
or savings of the surgical procedure will not be
elucidated. The societal perspective includes both
short- and long-term outcomes. If costs outside the
Fig. 2 Reported costs from included studies
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hospital are not included, investments with high
purchasing costs may seem less attractive.
The time horizon was reported in a few studies and
most often costs from the inpatient stay and up to 4
months after surgery was given. With a short follow-up
time after surgery cost drivers as rehabilitation and re-
turn to work are missing and all costs and effects from
surgery are therefore not displayed [3, 44, 45].
Most of the studies used gross-costing based on data
from records, chart reviews, or databases. However,
when comparing RMIS with other surgical procedures,
gross-costing lacks specificity and primarily defines a
total budget instead of detailed data. In a pragmatic
world, micro-costing is possible from a single hospital,
whereas gross-costing data may be the only available
data suitable to perform large-scale analyses. Micro-cost-
ing is desirable but may be very costly and time
consuming to collect. If health care cost analyses have
omitted clarity of which cost items they have included it
may have a great impact on the transparency and hence
the conclusions being used for decision making. Costs of
operative procedures should be transparent and state
which cost drivers are included and whether indirect
costs such as cleaning and staff salary are included in
the calculation. It may be difficult to rank the most im-
portant cost items in cost studies depending of the aim
and data available. One of the most crucial cost items is
the purchasing and maintenance costs of the robotic
platform. This will affect the result and should be very
clearly stated. The operation time may seem as an im-
portant cost item, where the exact time can influence
the overall costs. When using charges, the overall costs
are often based on an average of utensils, staff salary and
operation time etc. for the specific operation and it is
not possible to measure the smaller variations in time
consumption. Even though robotic operations have
shorter length of stay compared to open surgery, the
taxes may seem unaffected. Hospitals are paid a fixed
price for each patient treated.
The purchase of the robotic platform and the mainten-
ance costs were rarely included although they represent
an important opportunity costs and have a potential to
display major impact on the cost analyses. An increased
number of operations per year will decrease the cost per
operation [2, 3] but only a few studies included the
number of annual procedures or procedures performed
per robotic platform. Of notice, Reynisson, P. et al.
reported twice as high in-patient charge compared to
other studies due to a minor depreciation time of the
robot and a decreased number of yearly operations [18].
They also reported investment and equipment costs to
be lower in North America than in Europe which should
be taken into account when comparing the costs
between countries [18].
Staff salaries may represent the most expensive cost
driver when estimating the total costs. Only one study
included staff salaries as a transparent cost estimation,
dividing the time spent on the operation by the hourly
wage [14]. A study by Lonnerfors, C. et al. defined major
cost drivers influencing the hospital costs as duration of
operating time and length of inpatient stay [17]. The
majority of the studies did not report key cost items thus
decreasing the generalizability.
Hospital charges based on what a health care provider
bills for the service may be easily obtained from databases.
However, hospital charges do not reflect the actual ex-
penses; rather they represent local estimations of costs re-
lated to specific procedures. There can be great variations
in the charges due to either over- or underestimation of the
actual costs of hospital care, time variation, or variation in
profit [32, 46]. Hence, use of the charging system may be
inappropriate and prevent comparisons across countries or
institutions due to variations in organizational structures,
range of health care facilities, and different budgets.
Several studies have documented that great expertise
with RMIS improves the surgical outcome in terms of
decreased operation time, shorter length of stay and a de-
crease in readmissions [18, 26, 34, 38]. Many of the studies
mentioned the importance of the learning curve of RMIS
but did not adjust for it in the analysis. Laursen et al. ex-
amined the costs of RMIS in 7670 women over a period
of 7 years showing costs to depend on the learning curve
of RMIS [47]. Hence, although difficult to account for, the
learning curve may represent an important cost driver.
Conclusions
Inadequate reporting of the study perspective, short time
horizon, and use of charge data decreased the methodo-
logical quality in studies of resource use and costs related
to RMIS within gynecology. Few studies complied with
the methodological items in the CHEERS checklist and
the methodological quality was generally assessed low. If
the results lack transparency of included cost elements it
can lead to incorrect incentives for decision makers lea-
ding to inefficient allocation of hospital resources.
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